Business
Marina Biotech Receives Three Notices of Allowances from the USPTO and an Intent to Grant Notice from the European Patent Office
Marina Biotech Receives Three Notices of Allowances from the USPTO and an Intent to Grant Notice from the European Patent Office.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"Marina Biotech Receives Three Notices of Allowances from the USPTO and an Intent to Grant Notice from the European Patent OfficeExpands Patent Protection for SMARTICLES® and DiLA2TM Delivery Platforms Bothell, WA, May 10, 2012 – Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent applications U.S. 12/004,154 (‘154), U.S. 10/594,553 (‘553), and U.S. 10/505,107 (‘107). Further, the European Patent Office provided a notice of an Intent to Grant for European patent application EP09165106.7. The patents expand protection to the Company’s liposomal-based delivery capability which includes both the SMARTICLES and DiLA2 platforms as well as an emerging third platform which represents a combination of key delivery attributes from these two platforms.“We are pleased to see that the USPTO and EPO continue to recognize the significance of our DiLA2 and SMARTICLES delivery technologies,” stated Richard Ho, M.D., Ph.D., Executive Vice President, Research and Development at Marina Biotech. “Since the acquisition of the SMARTICLES delivery technology, an amphoteric-based liposomal delivery system, in 2010 from Novosom AG, the Company has invested substantial resources to advance both this technology and the DiLA2 delivery technology, an amino acid-based liposomal delivery system. Part of this endeavor involved determining whether the DiLA2 and SMARTICLES delivery technologies could be integrated, and novel formulations developed that take advantage of the benefits of each platform. To date, our R&D team has successfully developed numerous formulations that represent the successful ‘marriage’ of these two platforms. We expect to continue to exploit these technologies and utilize them for the effective, efficient and safe delivery of both single- and double-stranded oligonucleotide therapeutics.”The claims of the ‘154 patent application broadly cover nucleic acid delivery formulations based on novel sterol derivative compounds, and the claims of the ‘553 patent application cover a broad number of novel amphoteric formulations. Both the ‘154 and ‘55...